In the last trading session, 1.4 million IN8bio Inc (NASDAQ:INAB) shares changed hands as the company’s beta touched 0.22. With the company’s per share price at $0.15 changed hands at -$0.01 or -6.27% during last session, the market valuation stood at $12.28M. INAB’s last price was a discount, traded about -1060.0% off its 52-week high of $1.74. The share price had its 52-week low at $0.16, which suggests the last value was -6.67% down since then. When we look at IN8bio Inc’s average trading volume, we note the 10-day average is 1.04 million shares, with the 3-month average coming to 5.45 million.
Analysts gave the IN8bio Inc (INAB) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 2 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended INAB as a Hold, 2 felt it is a Buy and 0 rated the stock as Underweight. IN8bio Inc’s EPS for the current quarter is expected to be -0.07.
IN8bio Inc (NASDAQ:INAB) trade information
Instantly INAB was in red as seen at the end of in last trading. With action -22.95%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -41.25%, with the 5-day performance at -22.95% in the red. However, in the 30-day time frame, IN8bio Inc (NASDAQ:INAB) is -41.59% down. Looking at the short shares, we see there were 1.67 million shares sold at short interest cover period of 0.67 days.
According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -13.22%. The 2025 estimates are for IN8bio Inc earnings to increase by 63.45%, but the outlook for the next 5-year period is at 23.82% per year.
INAB Dividends
IN8bio Inc is expected to release its next quarterly earnings report on 2025-Mar-12.
IN8bio Inc (NASDAQ:INAB)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 5.09% of IN8bio Inc shares while 36.96% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 38.94%. There are 36.96% institutions holding the IN8bio Inc stock share, with AIGH CAPITAL MANAGEMENT LLC the top institutional holder. As of 2024-06-30, the company held 4.7157% of the shares, roughly 2.13 million INAB shares worth $1.8 million.
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 3.2892% or 1.42 million shares worth $1.21 million as of 2024-06-30.
Among Mutual Funds, the top two as of Jan 31, 2025 were Franklin Strategic Series-FRANKLIN BIOTECHNOLOGY DISCOVERY FUND and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund . With 2.09 shares estimated at $0.32 million under it, the former controlled 2.57% of total outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund held about 1.17% of the shares, roughly 952.49 shares worth around $0.14 million.
